| Title |
Sequential Therapy Versus Standard Triple-Drug Therapy for Helicobacter pylori Eradication: a Systematic Review of Recent Evidence
|
|---|---|
| Published in |
Drugs, April 2013
|
| DOI | 10.1007/s40265-013-0053-z |
| Pubmed ID | |
| Authors |
Vikram Kate, Raja Kalayarasan, Nilakantan Ananthakrishnan |
| Abstract |
Several alternative treatment regimens for Helicobacter pylori eradication have been proposed since the efficacy of standard triple therapy has declined over time, and sequential therapy is one of them. The purpose of this systematic review is to analyze and compare the efficacy, adverse effects and cost of sequential therapy with that of standard triple therapy for H. pylori infection. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Russia | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 42 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 2% |
| Unknown | 41 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 17% |
| Student > Bachelor | 7 | 17% |
| Other | 5 | 12% |
| Student > Master | 4 | 10% |
| Student > Doctoral Student | 2 | 5% |
| Other | 6 | 14% |
| Unknown | 11 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 31% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Immunology and Microbiology | 2 | 5% |
| Business, Management and Accounting | 2 | 5% |
| Psychology | 2 | 5% |
| Other | 9 | 21% |
| Unknown | 12 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 May 2013.
All research outputs
#15,272,611
of 22,711,242 outputs
Outputs from Drugs
#2,790
of 3,250 outputs
Outputs of similar age
#120,007
of 193,475 outputs
Outputs of similar age from Drugs
#25
of 35 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,250 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 193,475 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.